Browse the evidence

Obesity is associated with increased risk of various cancers (breast, colorectal, endometrial, etc.) through mechanisms involving chronic inflammation, insulin resistance, and hormonal changes.

Maintaining a healthy weight reduces your risk of several cancers. Focus on sustainable lifestyle changes to lower your risk.

Obesity is a complex chronic disease requiring multidisciplinary care, and stigma contributes to morbidity and mortality.

Understand that obesity is a chronic disease, not a personal failure. Seek care from a multidisciplinary team that treats you with respect and empathy, as stigma can worsen health outcomes.

GLP-1 receptor agonists significantly increase the volume of retained gastric contents in fasting patients, but this does not translate to a statistically significant increase in actual pulmonary aspiration rates.

If you take a GLP-1 drug (like Ozempic or Wegovy) and have surgery, your stomach might stay fuller longer, but you are not significantly more likely to vomit into your lungs than someone who doesn't take it. Do not stop your medication without asking your surgeon or anesthesiologist, as modern guidelines suggest continuing it for most people while using other safety checks like ultrasound.

Endogenous GIP acts as an incretin that potentiates glucose-stimulated insulin secretion, and its inhibition via GIP receptor antagonists reveals this physiological role.

GIP naturally helps your body release insulin after eating. Early treatments tried adding more GIP, but it didn't work well in diabetics. New research shows that blocking GIP's natural signal helps scientists understand its true role, which is still to boost insulin, even in diabetes.

Tirzepatide is associated with a significantly higher incidence of gastrointestinal adverse events (nausea, vomiting, diarrhea, decreased appetite) compared to placebo, insulin, and GLP-1 RAs, particularly at higher doses.

Expect gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These are common but often improve over time. Discuss management strategies with your doctor.

Lean mass is an inaccurate proxy for muscle mass in GLP-1 trials because it includes organs, bone, and fluids; MRI-based muscle volume z-scores provide a more accurate assessment of muscle health.

Do not rely solely on 'lean mass' numbers from standard scales or DXA scans to judge your muscle health. These numbers include water and organ weight. For a true picture of muscle, look at muscle volume and quality via advanced imaging like MRI, which shows if muscle fat is decreasing.

Higher fasting insulin levels and lower Sex Hormone-Binding Globulin (SHBG) levels causally increase the risk of PCOS, acting as key metabolic drivers of the syndrome.

Managing insulin resistance is crucial for PCOS prevention and management. High insulin and low SHBG are causal factors. Lifestyle interventions that improve insulin sensitivity (diet, exercise) can mitigate PCOS risk by addressing these metabolic drivers.

Obesity is a neurobiological disorder driven by genetic and environmental interactions that dysregulate brain-controlled energy homeostasis, rather than a failure of individual willpower.

Understand that obesity is a complex biological condition influenced by genetics and environment, not a simple failure of willpower. This perspective shifts the focus from self-blame to seeking effective, biologically-targeted treatments and lifestyle adjustments that work with your body's natural regulatory systems.

Obesity is a complex, chronic, multifactorial disease driven by genetic, epigenetic, psychosocial, and microenvironmental factors, rather than solely an energy imbalance.

Stop viewing obesity as a simple failure of willpower or calorie counting. Recognize it as a complex biological disease involving genetics, gut health, and stress. This shifts the focus from self-blame to seeking comprehensive medical and lifestyle interventions that address these underlying drivers.

Increased economic development and industrialization are associated with higher obesity rates primarily due to increased caloric intake and diet quality (specifically ultraprocessed foods), rather than reduced physical activity or energy expenditure.

Stop blaming your lack of exercise for your weight gain. This research shows that moving less doesn't necessarily mean you burn significantly less energy than a highly active person of the same size. The real driver of obesity in modern societies is what you eat, specifically the high proportion of ultraprocessed foods that disrupt satiety and increase absorption. Focus on reducing ultraprocessed food intake rather than obsessing over increasing physical activity expenditure to fix obesity.

Lifestyle treatment alone has modest or little long-term effect on weight loss, particularly in adults, and is often insufficient for sustainable weight maintenance due to biological drivers like hunger.

Do not blame yourself if lifestyle changes alone haven't led to lasting weight loss. The paper confirms that lifestyle treatment often has modest long-term effects due to biological factors like hunger. This is a common challenge, not a personal failure.

Hyperglycemia and insulin resistance drive Coronary Microvascular Dysfunction (CMD) through oxidative stress, inflammation, and reduced nitric oxide (NO) bioavailability, leading to endothelial dysfunction.

Controlling blood sugar and insulin resistance is critical not just for nerves and kidneys, but for heart health. High glucose and insulin resistance directly damage the heart's small blood vessels by creating oxidative stress and reducing the body's ability to dilate blood vessels (NO bioavailability).

GLP-1 receptor agonists are associated with an increased risk of gastrointestinal side effects (nausea, vomiting, diarrhea) and rare serious adverse events (gallbladder disorders, pancreatitis), as well as emerging risks related to delayed gastric emptying affecting anesthesia and endoscopy.

Be aware that nausea, vomiting, and diarrhea are common when starting GLP-1 medications, but they often improve over time. Serious side effects like gallbladder issues or pancreatitis are rare but require medical attention. If you need surgery or a colonoscopy, inform your provider, as they may need to adjust your medication schedule to prevent complications like aspiration.

GLP-1 receptor agonists provide significant cardiorenal protection, reducing major adverse cardiovascular events (MACE) and kidney-related complications in patients with type 2 diabetes and/or cardiovascular disease, independent of weight loss.

GLP-1 medications do more than help you lose weight; they actively protect your heart and kidneys. For people with diabetes or existing heart/kidney issues, these drugs significantly lower the risk of heart attacks, strokes, and kidney failure. This protection is a key reason why doctors prescribe them, offering benefits beyond just the scale.

Intensive lifestyle intervention (ILI) focused on weight loss does not significantly reduce all-cause mortality in older adults with type 2 diabetes and overweight/obesity compared to diabetes support and education (DSE) over a median of 16.7 years.

For older adults with type 2 diabetes, engaging in intensive lifestyle programs (diet and exercise) is recommended to improve quality of life, fitness, and metabolic health, but should not be undertaken with the expectation that it will significantly extend lifespan compared to standard diabetes education. The intervention is safe and does not increase mortality risk.

Enteroendocrine cells (EECs) act as chemosensors that secrete hormones (e.g., GLP-1, PYY, CCK) in response to luminal nutrients, regulating appetite, glucose metabolism, and gut motility.

Your gut contains specialized cells that sense what you eat and send signals to your brain and pancreas to regulate hunger and blood sugar. This natural system can be targeted by medications to treat metabolic diseases.

Obesity is an independent proarrhythmic risk factor for both atrial and ventricular arrhythmias, mediated by structural remodeling (atrial/ventricular dilation, epicardial fat infiltration) and electrophysiological changes (prolonged QTc, P-wave dispersion).

Obesity directly increases the risk of heart rhythm problems (atrial and ventricular arrhythmias) through structural changes like heart enlargement and fat infiltration around the heart. This risk exists independently of other conditions like high blood pressure. Weight loss is a key intervention to reduce this risk.

Long-term weight loss maintenance is physiologically opposed by metabolic adaptation (reduced energy expenditure) and hyperphagia (increased appetite), driven by neuroendocrine signals like leptin, making weight regain the default biological state.

Understand that after weight loss, your body biologically fights to regain weight through increased hunger and slower metabolism. This is not a failure of willpower but a physiological defense. Successful maintenance requires acknowledging this biological reality and often necessitates ongoing, lifelong behavioral or medical support to counter these natural drives.

The hypothalamus regulates body fat mass through a defended set point, where afferent signals from gut hormones (GLP-1, CCK, ghrelin) and adipose tissue (leptin) modulate food intake and energy expenditure.

Your brain uses signals from your gut (like GLP-1 and ghrelin) and fat cells (leptin) to decide how hungry you are and how much energy you burn. In obesity, this system is broken, defending a higher weight.

Body Mass Index (BMI) is an inadequate and potentially misleading metric for assessing individual cardiometabolic risk because it fails to account for regional fat distribution and ectopic lipid deposition, which are the true drivers of disease.

Stop using BMI as your primary health metric. Instead, focus on waist circumference and metabolic markers (blood pressure, lipids, glucose). If you have a high BMI but a small waist and good metabolic markers, your risk may be low. Conversely, if you have a normal BMI but a large waist, your risk may be high. Prioritize lifestyle habits (diet quality, physical activity) that reduce visceral fat rather than just total weight.

Obesity is a chronic disease characterized by physiological dysregulation of fat mass, not merely a result of willful behavioral choices.

Stop blaming yourself for your weight. Obesity is a chronic disease driven by your body's physiology, not just your willpower. Seek medical treatment because your body is fighting you, and you need professional help to manage it.

SGLT2 inhibitors improve cardiovascular outcomes in heart failure patients, including those with preserved and reduced ejection fraction, independent of diabetes status.

If you have heart failure, ask your doctor about SGLT2 inhibitors. They are now recommended for heart failure patients regardless of whether they have diabetes, as they significantly improve outcomes.

Exposure to aerial environmental stressors, specifically fine particulate matter (PM2.5) and gaseous pollutants, causes cardiovascular disease and mortality through systemic inflammation, oxidative stress, and autonomic nervous system imbalance.

Monitor local air quality indices (AQI) and smog alerts. On days with high pollution, limit prolonged outdoor exertion, especially near traffic. Consider using air purifiers indoors and keeping windows closed during peak pollution times. This is a modifiable risk factor that acts independently of your diet and exercise habits.

Resmetirom, a THR-β agonist, improves histologic features of MASLD, including resolution of steatohepatitis without worsening fibrosis and improvement in fibrosis stage, in patients with F1-F3 fibrosis.

Resmetirom is the first FDA-approved drug for MASH. In clinical trials, doses of 80mg or 100mg taken daily for 52 weeks significantly improved liver inflammation and fibrosis compared to placebo. It is an option for those with F1-F3 fibrosis.